- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02442531
A Study of CriPec® Docetaxel Given to Patients With Solid Tumours (NAPOLY)
A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® Docetaxel in Patients With Solid Tumours
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- At least 18 years old
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Estimated life expectancy of at least 12 weeks
Ability and willingness to give written informed consent and to comply with the requirements of the study
For Part 1:
Patients with pathologically confirmed diagnosis of advanced, recurrent and progressive solid tumours that are refractory to standard therapy or for whom no standard therapy exists and with measurable or evaluable disease according to RECIST 1.1.
For Part 2:
- Patients with pathologically confirmed diagnosis of advanced, recurrent and progressive cancer with measurable disease according to RECIST 1.1 of a histological type that are refractory to standard therapy or for whom no standard therapy exists and where treatment with a taxane is an appropriate treatment option.
Exclusion Criteria:
- Less than 4 weeks since the last treatment of chemotherapy, biological therapy, immunotherapy or systemic radiotherapy (except palliative radiation delivered to <20% of bone marrow), and less than 6 weeks for nitrosoureas and mitomycin C prior to Cycle 1 Day 1.
- Current or recent (within 4 weeks prior to Cycle 1 Day 1) treatment with another Investigational Product or participation in another investigational interventional study.
- Symptomatic brain metastases.
- Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) that have not resolved to ≤ grade 2 (as defined by CTCAE version 4.03).
Inadequate bone marrow function at screening as evidenced by any of the following:
- Absolute Neutrophil Count (ANC) < 1.5 x 109/L.
- Platelet count < 100 x 109/L.
- Haemoglobin < 6.0 mmol/L (< 9.6 g/dL). The patient should not have received a transfusion or growth factors for these abnormalities in the 7 days prior to Cycle 1 Day 1.
- Serum (total) bilirubin > 1.5 x the Upper Limit of Normal (ULN) for the institution if no liver metastases (> 2 x ULN in patients with liver metastases).
- AST or ALT > 2.5 x ULN if no liver metastases (> 5x ULN in patients with liver metastases).
- Alkaline phosphatase levels > 2.5 x ULN if no liver metastases (> 5 x ULN in patients with liver metastases, or > 10 x ULN in patients with bone metastases).
- Increased plasma prothrombin time or International Normalized Ratio (INR), consequence of reduced hepatic production of Vitamin K.
- Hepatitis B surface antigen or hepatitis C positivity with abnormal liver function tests.
Medical history of:
- Nonalcoholic steatohepatitis (NASH).
- History of human immunodeficiency virus (HIV) antibody positive or use of antiretroviral therapy.
- Alcoholic and autoimmune hepatitis.
- Ischemic hepatitis, Cardiovascular dysfunction or impaired liver oxygenation, including hypotension or right heart failure.
- Serum creatinine > 1.5 x ULN.
- Estimated Glomerular Filtration Rate of < 50 mL/min/1.73m2 calculated by Modification of Diet in Renal Disease (MDRD) formula or creatinine clearance of < 50 mL/min calculated by Cockcroft-Gault.
- Stroke within 6 months prior to Cycle 1 Day 1.
- Transient Ischemic Attack (TIA) within 6 months prior to Cycle 1 Day 1.
- Myocardial infarction within 6 months prior to Cycle 1 Day 1.
- Unstable angina.
- New York Heart Association (NYHA) Grade II or greater Congestive Heart Failure at screening.
- Serious cardiac arrhythmia requiring medication.
- Patients who are pregnant or breastfeeding.
- Absence of effective means of contraception in female patients of childbearing potential (defined as <2 years after last menstruation and not surgically sterile) or in male patients who are not surgically sterile and who have female partners of childbearing potential.
- Major surgical procedure (including open biopsy and excluding central line intravenous catheter) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
- Grade ≥2 motor or sensory neuropathy symptoms (as defined by CTCAE version 4.03).
- Known hypersensitivity to any of the Investigational Product's excipients or taxanes.
- History of drug or alcohol abuse in the opinion of the investigator within 3 years before screening.
- Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk for treatment-related complications.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: CriPec® docetaxel
Docetaxel containing nanoparticle
|
-3 weekly IV dose.
Dose escalation; start dose 15 mg/m2.
Number of cycles: 6 or until progression or unacceptable toxicity develops
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Part 1: Incidence of grade 3 or 4 adverse events (AEs) as a measure of safety and tolerability.
Tidsramme: 9 months
|
Part 1: Incidence of grade 3 or 4 adverse events (AEs) will be determined after escalating doses of CriPec® docetaxel once every three weeks.
|
9 months
|
Part 1: Incidence of clinical laboratory abnormalities as a measure of safety and tolerability.
Tidsramme: 9 months
|
Part 1: Incidence of laboratory abnormalities will be determined after escalating doses of CriPec® docetaxel once every three weeks.
|
9 months
|
Part 1: Incidence of electrocardiogram (ECG) abnormalities as a measure of safety and tolerability.
Tidsramme: 9 months
|
Part 1: Incidence of electrocardiogram (ECG) abnormalities will be determined after escalating doses of CriPec® docetaxel once every three weeks.
|
9 months
|
Part 2: Incidence of grade 3 or 4 adverse events (AEs) at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1.
Tidsramme: 9 months
|
Part 2: Incidence of grade 3 or 4 adverse events (AEs) at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.
|
9 months
|
Part 2: Incidence of clinical laboratory abnormalities at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1
Tidsramme: 9 months
|
Part 2: Incidence of clinical laboratory abnormalities at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.
|
9 months
|
Part 2: Incidence of electrocardiogram (ECG) abnormalities at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1
Tidsramme: 9 months
|
Part 2: Incidence of electrocardiogram (ECG) abnormalities at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.
|
9 months
|
Part 1 and 2: Pharmacokinetic profile of CriPec® docetaxel following IV infusion
Tidsramme: First two cycles of CriPec® docetaxel (each cycle is 3 weeks)
|
Pharmacokinetic parameters such as time to peak concentration (Tmax), peak concentration (Cmax), volume of distribution (Vd), half life (t1/2), total body clearance (CL) and area under the concentration-time curve (AUC) will be determined using plasma concentration data.
|
First two cycles of CriPec® docetaxel (each cycle is 3 weeks)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Early signs of anti-tumor efficacy (overall response rate [ORR]) of CriPec® docetaxel
Tidsramme: 18 months in total for part 1 and 2
|
18 months in total for part 1 and 2
|
Early signs of anti-tumor efficacy (duration of response) of CriPec® docetaxel
Tidsramme: 18 months in total for part 1 and 2
|
18 months in total for part 1 and 2
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CT-CL01
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med CriPec® docetaxel
-
Amsterdam UMC, location VUmcCristal TherapeuticsAfsluttet
-
Cristal TherapeuticsAfsluttetKræft | LivmoderhalskræftHolland, Belgien, Det Forenede Kongerige
-
Hoffmann-La RocheAfsluttetBrystkræftKina, Forenede Stater, Sydafrika, Den Russiske Føderation, Thailand, Bosnien-Hercegovina, Tjekkiet, Indien, Polen
-
H. Lee Moffitt Cancer Center and Research InstituteAstraZenecaAfsluttetIkke-småcellet lungekræftForenede Stater
-
Korean Breast Cancer Study GroupUkendtMetastatisk brystkræft | Tilbagevendende brystkræftKorea, Republikken
-
Hospira, now a wholly owned subsidiary of PfizerAfsluttetKræftDet Forenede Kongerige, Den Russiske Føderation
-
Merck Sharp & Dohme LLCAfsluttetLokalt avancerede, metastatiske faste tumorer
-
Merck Sharp & Dohme LLCGOG Foundation; European Network of Gynaecological Oncological Trial Groups...Aktiv, ikke rekrutterendeEndometriale neoplasmerAustralien, Forenede Stater, Tyskland, Israel, Korea, Republikken, Polen, Kalkun, Belgien, Brasilien, Canada, Chile, Kina, Tjekkiet, Danmark, Finland, Ungarn, Irland, Italien, Japan, Holland, New Zealand, Norge, Den Russiske Føderation, Spani... og mere
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RekrutteringHER2-positiv brystkræftKina
-
Institut de Recherches Internationales ServierAfsluttetLymfom | Avancerede solide tumorerForenede Stater, Spanien, Frankrig